Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05309668 · OUTCOME

Selumetinib and N-desmethyl Selumetinib AUC0-6 Derived After Single and Multiple Dose Administration

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN · Source last updated 2026-08-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
h*ng/mL
Interval / dispersion
Geometric Coefficient of Variation
Time frame
Pre-dose and 1, 2, 3, 4 and 6 hours after selumetinib single dose on the first day of study treatment (Cycle 1 Day 1). Pre-dose, 1, 2, 3, 4 and 6 hours post-dose on Cycle 2 Day 1 (each cycle is 28 days)

What was measured

To further evaluate the PK of the granule formulation.

Analysis population: Pharmacokinetic analysis set was used for analysis. Some records were excluded for given visits and analytes due to missing concentration data, issues taking the medication and usage of prohibited medications.

Groups in this outcome

Global Cohort 1

Global Cohort 1 (\>=4 to \<7 years)

Global Cohort 2

Global Cohort 2 (\>=1 to \<4 years)

Total in Global

Global Cohorts (\>=1 to \<7 years)

Japan Cohort

Japan Cohort (\>=1 to \<7 years)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Global Cohort 115
Global Cohort 217
Total in Global32
Japan Cohort4

Reported measurements

Cycle 1 Day 1: Selumetinib

Analysis denominator · Participants

GroupSource count
Global Cohort 113
Global Cohort 215
Total in Global28
Japan Cohort4
Values in h*ng/mL · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Global Cohort 1151630.42Not reportedNot reportedNot reported
Global Cohort 2135237.13Not reportedNot reportedNot reported
Total in Global142634.05Not reportedNot reportedNot reported
Japan Cohort130332.65Not reportedNot reportedNot reported
Cycle 1 Day 1: N-desmethyl selumetinib

Analysis denominator · Participants

GroupSource count
Global Cohort 113
Global Cohort 215
Total in Global28
Japan Cohort4
Values in h*ng/mL · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Global Cohort 1118.331.40Not reportedNot reportedNot reported
Global Cohort 299.7336.98Not reportedNot reportedNot reported
Total in Global108.035.04Not reportedNot reportedNot reported
Japan Cohort96.2228.26Not reportedNot reportedNot reported
Cycle 2 Day 1: Selumetinib

Analysis denominator · Participants

GroupSource count
Global Cohort 115
Global Cohort 214
Total in Global29
Japan Cohort4
Values in h*ng/mL · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Global Cohort 1241243.55Not reportedNot reportedNot reported
Global Cohort 2167248.14Not reportedNot reportedNot reported
Total in Global202149.40Not reportedNot reportedNot reported
Japan Cohort163031.40Not reportedNot reportedNot reported
Cycle 2 Day 1: N-desmethyl selumetinib

Analysis denominator · Participants

GroupSource count
Global Cohort 115
Global Cohort 214
Total in Global29
Japan Cohort4
Values in h*ng/mL · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Global Cohort 1145.631.30Not reportedNot reportedNot reported
Global Cohort 2102.435.17Not reportedNot reportedNot reported
Total in Global122.837.71Not reportedNot reportedNot reported
Japan Cohort113.014.43Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        30.42
        value
        1516
      2. group Id
        OG001
        spread
        37.13
        value
        1352
      3. group Id
        OG002
        spread
        34.05
        value
        1426
      4. group Id
        OG003
        spread
        32.65
        value
        1303
    denoms
    1. counts
      1. group Id
        OG000
        value
        13
      2. group Id
        OG001
        value
        15
      3. group Id
        OG002
        value
        28
      4. group Id
        OG003
        value
        4
      units
      Participants
    title
    Cycle 1 Day 1: Selumetinib
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        31.40
        value
        118.3
      2. group Id
        OG001
        spread
        36.98
        value
        99.73
      3. group Id
        OG002
        spread
        35.04
        value
        108.0
      4. group Id
        OG003
        spread
        28.26
        value
        96.22
    denoms
    1. counts
      1. group Id
        OG000
        value
        13
      2. group Id
        OG001
        value
        15
      3. group Id
        OG002
        value
        28
      4. group Id
        OG003
        value
        4
      units
      Participants
    title
    Cycle 1 Day 1: N-desmethyl selumetinib
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        43.55
        value
        2412
      2. group Id
        OG001
        spread
        48.14
        value
        1672
      3. group Id
        OG002
        spread
        49.40
        value
        2021
      4. group Id
        OG003
        spread
        31.40
        value
        1630
    denoms
    1. counts
      1. group Id
        OG000
        value
        15
      2. group Id
        OG001
        value
        14
      3. group Id
        OG002
        value
        29
      4. group Id
        OG003
        value
        4
      units
      Participants
    title
    Cycle 2 Day 1: Selumetinib
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        31.30
        value
        145.6
      2. group Id
        OG001
        spread
        35.17
        value
        102.4
      3. group Id
        OG002
        spread
        37.71
        value
        122.8
      4. group Id
        OG003
        spread
        14.43
        value
        113.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        15
      2. group Id
        OG001
        value
        14
      3. group Id
        OG002
        value
        29
      4. group Id
        OG003
        value
        4
      units
      Participants
    title
    Cycle 2 Day 1: N-desmethyl selumetinib
denoms
  1. counts
    1. group Id
      OG000
      value
      15
    2. group Id
      OG001
      value
      17
    3. group Id
      OG002
      value
      32
    4. group Id
      OG003
      value
      4
    units
    Participants
description
To further evaluate the PK of the granule formulation.
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    Global Cohort 1 (\>=4 to \<7 years)
    id
    OG000
    title
    Global Cohort 1
  2. description
    Global Cohort 2 (\>=1 to \<4 years)
    id
    OG001
    title
    Global Cohort 2
  3. description
    Global Cohorts (\>=1 to \<7 years)
    id
    OG002
    title
    Total in Global
  4. description
    Japan Cohort (\>=1 to \<7 years)
    id
    OG003
    title
    Japan Cohort
param Type
GEOMETRIC_MEAN
population Description
Pharmacokinetic analysis set was used for analysis. Some records were excluded for given visits and analytes due to missing concentration data, issues taking the medication and usage of prohibited medications.
reporting Status
POSTED
time Frame
Pre-dose and 1, 2, 3, 4 and 6 hours after selumetinib single dose on the first day of study treatment (Cycle 1 Day 1). Pre-dose, 1, 2, 3, 4 and 6 hours post-dose on Cycle 2 Day 1 (each cycle is 28 days)
title
Selumetinib and N-desmethyl Selumetinib AUC0-6 Derived After Single and Multiple Dose Administration
type
SECONDARY
unit Of Measure
h*ng/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice